Abstract: The present invention relates to a powder mixture for the preparation of a granulate comprising as constituent at least a filler or at least an active ingredient or both and as granulation aid potassium sodium tartrate tetrahydrate (PST). Optionally constituents of the powder mixture to be granulated are binders, disintegrants and further customary auxiliaries. It was an object of the present invention to provide a powder mixture which can be granulated without adding a liquid but where the water for the granulation is released in-situ from PST. An additional drying step is not required.

Abstract: The present invention relates to a powder mixture for the preparation of a granulate comprising as constituent at least a filler or at least an active ingredient or both and as granulation aid Magnesium diacetate×4H2O and/or Magnesium dichloride×6H2O and/or Magnesium sulfate×7H2O and/or Disodium sulfate xH2O and/or Sodium thiosulfate×5H2O and/or Na3PO4×12H2O and/or Na2HPO4×12H2O/7H2O and/or Sodium acetate×3H2O. Optionally constituents of the powder mixture to be granulated are binders, disintegrants and further customary auxiliaries. It was an object of the present invention to provide a powder mixture which can be granulated without adding a liquid but where the water for the granulation is released in-situ from Magnesium diacetate×4H2O and/or Magnesium dichloride×6H2O and/or Magnesium sulfate×7H2O and/or Disodium sulfate xH2O and/or Sodium thiosulfate×5H2O and/or Na3PO4×12H2O and/or Na2HPO4×12H2O/7H2O and/or Sodium acetate×3H2O. An additional drying step is not required.

Abstract: The present invention relates to a direct tableting auxiliary composition based on lactose powder mixed intimately with a water-soluble polyethylene glycol-polyvinyl alcohol graft copolymeras binder, a lubricants, a colorant and optionally a crosslinked insoluble polyvinylpyrrolidone as tablet disintegrating agent.

Abstract: The present invention relates to a direct tableting auxiliary composition based on lactose powder mixed intimately with a water-soluble polyethylene glycol-polyvinyl alcohol graft copolymeras binder, crosslinked insoluble polyvinylpyrrolidone as tablet disintegrating agent and a lubricant.

Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Abstract: The present invention relates to novel polyurethanes based on a diisocyanate, a carboxylic acid functionalized diol and an acid-free diol, their use as pharmaceutical excipients for improving gastrointestinal absorption, the respective pharmaceutical dosage forms and methods for making the polyurethanes.

Abstract: Copolymer, wherein structural units are derived from: i) an acrylic carboxylic acid monomer (4 to 18% by weight), selected from the group consisting of acrylic acid and methacrylic acid, ii) a 5 hydrophobic methacrylate (more than 8% by weight), selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate, iii) a N-vinyl lactam, selected from a group consisting of N-vinyl pyrrolidone and N-vinylcaprolactam and optionally iv) 2-hydroxyethyl methacrylate, with the proviso that the total amount of structural units derived from the monomer groups adds up to 100% by weight, and the calculated solubility parameter SP of 10 the copolymer is between 22.0 and 25.0 MPa1/2, and the use of the copolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization of an active ingredient in an aqueous environment of a human or animal body.

Abstract: The use of powder-form, crosslinked, water-insoluble, low-swelling polyacrylates as disintegrants for solid pharmaceutical dosage forms.

Abstract: The present invention relates to processes for producing microparticles having, in their interior, at least one cavity which is connected via pores to the surface of the microparticles and which have been laden with at least one organic active of low molecular weight. The invention especially relates to a process for loading microparticles with at least one organic active of low molecular weight, wherein the active has been embedded in a matrix and/or the pores of the microparticles have been closed by means of a substance applied to the surface of the microparticles. The invention additionally relates to a process for sealing microparticles laden with at least one organic active of low molecular weight. The invention also relates to compositions of microparticles laden with at least one active of low molecular weight and to the use thereof.

Abstract: A finely divided binder in powder form consisting of a polyethylene glycol-polyvinyl alcohol graft polymer particles, wherein the particles have an average particle size D[4,3] in the range of from 10 to 70 ?m.

Abstract: The use of powder-form, crosslinked, water-insoluble, low-swelling polyacrylates as disintegrants for solid pharmaceutical dosage forms.

Abstract: A method for stabilizing cells in cell culture production, the method comprising culturing a cell line capable of expressing proteins in cell culture media, and supplementing said cell culture media with a graft polymer in which N-vinyl caprolactam and vinyl acetate moieties are grafted on a polyethylene glycol backbone.

Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Abstract: A finely divided binder in powder form consisting of a polyethylene glycol-polyvinyl alcohol graft polymer particles, wherein the particles have an average particle size D[4,3] in the range of from 10 to 70 ?m.

Abstract: Water-soluble polymeric salts of medicaments sparingly soluble in water consisting of a cationogenic medicament which, in uncharged form or as hydrochloride, has a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice, and an anionogenic water-soluble polymer having a solubility in water of at least 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight.

Abstract: Process for providing purified polyether block copolymers comprising polyoxyethylene (PEO) and polyoxypropylene (PPO) moieties wherein the purified product is obtained by an ultrafiltration step of a solution of the polyether block copolymers and wherein the block copolymers are depleted in lower molecular impurities.

Abstract: A process for purification of polyether block copolymers comprising polyoxyethylene and polyoxypropylene moieties using sequential multi-column size exclusion chromatography apparatus operated as a counter current moving bed wherein a process cycle comprises the steps of.

Abstract: Water-soluble polymeric salts of medicaments sparingly soluble in water consisting of a cationogenic medicament which, in uncharged form or as hydrochloride, has a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice, and an anionogenic water-soluble polymer having a solubility in water of at least 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight.

Abstract: Use of a water-soluble polymer having a solubility in water of greater than 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight, for the formulation of basic active ingredients sparingly soluble in water, wherein the active ingredients in uncharged form or as hydrochloride have a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice.

Abstract: Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 ?m is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations.